Patent intelligence · WO
WO 2026107424
DÉRIVÉS DE N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
DÉRIVÉS DE N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARD…
Patent details — WO 2026107424
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 21, 2026
- Expiration
- May 16, 2046
- Applicant
- BRISTOL MYERS SQUIBB CO [US]
- CPC classes
- A61K 31/ 4375 A I, A61P 3/ 10 A I, A61P 9/ 04 A I, A61P 9/ 06 A I
Quick answer
WO 2026107424 (DÉRIVÉS DE N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE) is held by BRISTOL MYERS SQUIBB CO [US]. Status: granted. Granted May 21, 2026. Expires May 16, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRISTOL MYERS SQUIBB CO [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4375 A I, A61P 3/ 10 A I, A61P 9/ 04 A I, A61P 9/ 06 A I, A61P 9/ 12 A I, A61P 11/ 06 A I
More from BRISTOL MYERS SQUIBB CO [US]
Related pharmaceutical patents in our USPTO index.
-
US 20260152488
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS
granted -
US 20260144884
ANTI-LRRC15 ANTIBODY DRUG CONJUGATES
granted -
WO 2026112045
NICOTINAMIDES PYRAZOLYLIQUES ET CARBOXAMIDES PYRIMIDINIQUES EN TANT QU'INHIBITEURS DE CAMK2
granted -
WO 2026112047
AMIDES DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE CAMK2
granted -
WO 2026112386
COMPOSÉS D'OXOISOINDOLINYL PIPÉRIDINE-2,6-DIONE SUBSTITUÉS ET PROCÉDÉS DE DÉGRADATION DE PROTÉINES
granted -
US 20260144885
ANTI-LRRC15 ANTIBODIES AND USES THEREOF
granted -
WO 2026107420
DÉRIVÉS DE N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
granted -
WO 2026107143
COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS
granted
Frequently asked questions
What is US patent 2026107424?
WO 2026107424 (DÉRIVÉS DE N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE) is held by BRISTOL MYERS SQUIBB CO [US]. Status: granted. Granted May 21, 2026. Expires May 16, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026107424?
BRISTOL MYERS SQUIBB CO [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2026107424 expire?
Our index shows an expiration date of May 16, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.